PBS listing for $150,000 melanoma drug

The federal government has announced it will list the melanoma drug pembrolizumab (Keytruda) on the Pharmaceutical Benefits Scheme.

Patients with a concession card will now pay $6.10 while others will pay $37.70 per pembrolizumab prescription, which previously cost $150,000 a year.

Professor Grant McArthur from the Peter MacCallum Cancer Centre says pembrolizumab, an anti-PD1